{"id":564919,"date":"2025-09-24T00:00:00","date_gmt":"2025-09-24T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algomd0027-2025-biopharma-obesity-current-treatment-treatment-algorithms-claims-data-analysis-obesity-overweight-us\/"},"modified":"2026-04-23T11:16:47","modified_gmt":"2026-04-23T11:16:47","slug":"algomd0027-2025-biopharma-obesity-current-treatment-treatment-algorithms-claims-data-analysis-obesity-overweight-us","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algomd0027-2025-biopharma-obesity-current-treatment-treatment-algorithms-claims-data-analysis-obesity-overweight-us\/","title":{"rendered":"Obesity &#8211; Current Treatment &#8211; Treatment Algorithms: Claims Data Analysis &#8211; Obesity \/ Overweight (US)"},"content":{"rendered":"<p class=\"text-align-left\">As the prevalence of obesity rises, the demand for safe and effective treatments increases. Therapies mimicking <abbr title=\"glucagon-like peptide\">GLP<\/abbr>-1 and <abbr title=\"glucose-dependent insulinotropic polypeptide\">GIP<\/abbr> peptides\u2014hormones that regulate appetite and energy metabolism\u2014have set new standards in weight-loss drugs. Led by Novo Nordisk\u2019s Wegovy (semaglutide), these therapies are driving rapid growth of the obesity therapy market and are on a path to transform the therapeutic landscape. Wegovy and Eli Lilly\u2019s Zepbound (tirzepatide) are the most advanced antiobesity therapies, offering significantly greater weight-loss efficacy than that of Novo Nordisk&#8217;s Saxenda. Older treatments such as phentermine, Contrave, Qsymia, and Xenical are also losing favor despite their lower costs. This report provides in-depth analysis and insight into how prescription weight-loss drugs are used to treat obesity and how medical practice is evolving.<\/p>\n<p class=\"text-align-left\"><strong>Questions answered<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What patient shares do key therapies and brands garner by line oftherapy in newly diagnosed obese\/overweight patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed obese\/ overweight patients?<\/li>\n<li>How have the <abbr title=\"glucagon-like peptide\">GLP<\/abbr>-1 <abbr title=\"receptor agonist\">RA<\/abbr> products been integrated into the treatment algorithm, and what is their source of business?<\/li>\n<li>What percentage of obese\/overweight patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?<\/li>\n<li>What percentage of obese\/overweight patients are treated with monotherapy vs. combination therapy? What are the most used combinations?<\/li>\n<li>What are the product-level compliance and persistency rates among drug-treated patients?<\/li>\n<\/ul>\n<p class=\"text-align-left\"><strong>Product description<\/strong><\/p>\n<p class=\"text-align-left\">Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:<\/p>\n<ul class=\"BulletListStyle1 SCXW5042461 BCX0 round-bullets\">\n<li>Understand patient flow between lines of therapy.<\/li>\n<li>Evaluate your brand share against competitors.<\/li>\n<li>Accurately assess your source of business.<\/li>\n<li>Quantify opportunities at different stages of the treatment algorithm.<\/li>\n<\/ul>\n<p class=\"text-align-left\"><strong>Product enhancement<\/strong><\/p>\n<p class=\"text-align-left\">Treatment Algorithms: Claims Data Analysis leverages Clarivate\u2019s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.<\/p>\n<p class=\"text-align-left\"><strong>Key drugs covered<\/strong><\/p>\n<p class=\"text-align-left\">Tirzepatide, semaglutide, liraglutide, phentermine + topiramate <abbr title=\"fixed-dose combination\">FDC<\/abbr>, naltrexone + bupropion <abbr title=\"fixed-dose combination\">FDC<\/abbr>, orlistat<\/p>\n<p class=\"text-align-left\"><strong>Key analyses<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>Brand \/ therapy usage across patient sample<\/li>\n<li>Newly diagnosed patient analysis<\/li>\n<li>Treatment initiation and progression<\/li>\n<li>Line of therapy analysis<\/li>\n<li>Combination therapy analysis<\/li>\n<li>Source of business for recently treated patients<\/li>\n<li>Persistency and compliance analysis<\/li>\n<li>Product-level patient flow<\/li>\n<\/ul>\n<p class=\"text-align-left\"><strong>Key feature<\/strong><\/p>\n<p class=\"text-align-left\">Dashboard featuring interactive visuals, easy navigation, and expanded analyses<\/p>\n","protected":false},"template":"","class_list":["post-564919","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-product-current-treatment","biopharma-product-treatment-algorithms-claims-data-analysis","biopharma-geography-us","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/564919","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/564919\/revisions"}],"predecessor-version":[{"id":565120,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/564919\/revisions\/565120"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=564919"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}